Welcome to our new website. We have rebranded from Lamepro to Pharmanovia Benelux
The report celebrates the firm’s diversity and sets out ambitious environmental and sustainability targets London April…
More informationLONDON – Alastair Hay is leaving his position as Chief Corporate Development Officer at the global…
More informationPharmanovia officially welcomes Lamepro B.V into the group Basildon (UK), 28 February 2022 – Pharmanovia, The life…
More informationBasildon (UK), 10 November 2021 – Pharmanovia, the original medicines specialist globally, today announced that its…
More informationBasildon (UK), 8 September 2021 – Pharmanovia, the original medicines specialist globally, in conjunction with their…
More informationBasildon (UK), 30 July, 2021 – Pharmanovia is proud to announce their first global charity partnership…
More informationBasildon (UK), 20 July, 2021 – m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement…
More informationAmit Patel is retiring as CEO, will transition to the Advisory Committee James Burt will take…
More informationBasildon (UK), 3 June 2021 – Pharmanovia, the original medicines specialist globally announced the promotion of…
More informationBasildon (UK), 4 May 2021 – Atnahs, the original medicines specialist backed by PE investor Triton Partners,…
More informationBasildon (UK), 22 March 2021 – Atnahs has appointed Felipe Florez to the position of Chief Financial…
More informationBasildon (UK), 1 December 2020 – Atnahs (“Atnahs”), has acquired the commercial rights for Valium® (Diazepam) in…
More informationBasildon (UK), 19 March 2020 – On 11 March 2020 the World Health Organization (WHO) declared…
More informationBasildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company,…
More informationBasildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for…
More information